Background/Aims: Monoclonal antibodies (mAbs) are presently the most promising treatment against Ebola virus disease (EVD), and cocktail of two or more antibodies likely confers protection through complementary mechanisms. Zaire Ebolavirus (EBOV) glycoprotein (GP) and viral protein 40 (VP40) are targets for designing neutralizing antibodies. Currently, the antiviral therapeutics of mAb-cocktails are still limited solely to anti-GP antibodies，there is no Abs cocktail against Zaire EBOV GP and VP40, which both have important interactions with host cellular membrane. Methods: We used hybridoma technology to produce anti-Zaire EBOV GP mAb against GP receptor binding domain, and anti-Zaire EBOV VP40 mAbs against the N-terminal domain, the C-terminal domain, respectively; synthesized Zaire EBOV transcription and replication competent virus like particles (trVLPs), which model even all aspects of the EBOV life cycles in order to evaluate the anti-viral effect of mAbs. Then, we characterized the anti-Zaire EBOV trVLPs effect of anti-GP and VP40 mAbs in vitro by real time-PCR, immunofluorescence assay and western blot analysis. Results: Our results demonstrate that anti-GP or anti-VP40 mAbs effectively inhibit trVLPs replication. The cocktails of anti-GP and anti-VP40 mAbs, or between anti-VP40 mAbs, had synergistic anti-trVLPs effect. Meanwhile, the detailed DNA and amino acid sequences of the mAbs were checked. Conclusion: The study verifies neutralizing efficacy of anti-GP or anti-VP40 mAb, report promising cocktail of anti-GP and anti-VP40 mAb, or cocktail of two anti-VP40 mAbs. To our knowledge, this is the first account to report the important anti-viral effect of cocktails of anti-GP and anti-VP40 mAbs in vitro.
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Introduction
Ebola virus (EBOV) is a single-stranded, negative-sense RNA virus which exhibits a unique heterogeneous filamentous structure, was first reported in 1976 as the cause of the highly contagious zoonotic disease, Ebola viral disease (EVD) in humans and other primates [1] . Five different species of EBOV have been characterized: 1) Zaire virus (Zaire EBOV); 2) Sudan virus (Sudan EBOV); 3) Bundibugyo virus (Bundibugyo EBOV); 4) Taï Forest virus (Taï Forest EBOV); and 5) Reston virus (Reston EBOV) [2] . The EVD epidemic in Western Africa caused by Zaire EBOV in 2013-2016 and associated to 28, 712 cases and 11, 323 deaths in 11 countries [3, 4] , high viral transmissibility, and relatively high mortality rate has demonstrated EVD as a serious global health threat. To date, there is no effective direct acting anti-EBOV treatment.
Up to now, the current therapeutic methods for patients with suspected or confirmed EVD is limited. A few studies have examined the anti-viral effect of neutralizing Zaire EBOV antibody (Ab), and around 20 Zaire EBOV Abs have been identified and characterized [5] [6] [7] . Few of them, including the single antibody Ab114, the two-Abs cocktail MIL77E, and the 3-Abs cocktail MB-003, ZAb, and ZMapp™ were tested in non-human primate models; only ZMapp™ has reached phase II clinical trials [5, 6] .
EBOV GP and VP40 are currently the main targets for designing antibodies. GP is composed of ectodomain GP1 and a trans-membrane fusion domain GP2. The core of GP1 is subdivided into three domains: the glycan cap, the receptor binding domain (RBD), and the mucin-like domain (MLD) [8, 9] . The glycan cap is the outer part of GP1, which forms a chalice to protect the receptor binding sites from antibodies; the RBD sub domain is exposed to the host membrane surface, which carrying putative binding domain sites; the MLD sub domain sustains the linkage with GP2 and stabilizes the metastable pre-fusion conformation. Therefore, GP1 and GP2 orchestrate viral entry, including attachment, uptake, and fusion [10] [11] [12] .
The matrix protein VP40 of EBOV is also a promising therapeutic target of interest. VP40 is the most abundantly protein in EBOV, locates beneath the viral bilayer to ensure structural integrity of the particle. There are two structures in VP40: the N-terminal domain (NTD), regulates dimerization, mediates interaction with plasma membrane for efficient VP40-plasma membrane localization; the C-terminal domain (CTD), mediates membrane binding and oligomerization [13] . Although antiviral therapeutics targeting VP40 are still underway, it's proved that inhibition of VP40 oligomerization is an effective means of halting budding, and disturbance in the loop region of VP40, would likely contribute towards the discovery of novel EBOV inhibitors [14] [15] [16] .
The combination of antibodies (cocktail) has been proved for synergistic protection and becoming popular treatment methods, such as MIL77E, MB-003, and ZMapp™ mentioned above. However, most of the Abs, including the 3-Abs cocktail ZMapp™, were designed to target different epitopes of the EBOV GP [5, 6, 17] , with limited characterization of Abs against EBOV VP40. Up to now, there is no research characterizing a neutralizing Abs cocktail against Zaire EBOV GP and VP40. Therefore, based on the fact that both GP and VP40 have vital roles in Zaire EBOV life cycle, and both have important interactions with host cellular membrane or plasma membrane, we designed and synthesized specific monoclonal antibodies (mAbs) targeting the RBD of GP and two different regions of VP40 (NTD and CTD). On a basis of ZEBOV trVLPs system, we verify the neutralizing efficacy of each anti-GP or anti-VP40 mAb, and report promising cocktail of anti-GP and anti-VP40 mAbs, or cocktail of two anti-VP40 mAbs. Here we discuss novel cocktail of antibodies-mediated neutralization of virus infectivity in vitro. 
Materials and Methods
Ethics statement BALB/c mice studies for biomedical research were performed strictly according with the Institutional Guiding Principles. Informed consent (2018-543) was obtained from the Ethics Committee of the First Affiliated Hospital, School of Medicine, Zhejiang University.
Design and production of mAbs
Based on the amino acid sequence of GP and VP40 of Zaire Ebola virus (Gen Bank: AIE11908.1, and AJP15081.1), we designed peptides targeting fragments of GP and VP40, respectively. The peptides were selected by carrier Keyhole Limpet Hemocyanin (KLH, Sigma, St. Louis, MO, USA). Then, the peptideKLHs compounds were inoculated into BALB/c mice. Later, splenocytes derived from the immunized mice were fused with the myeloma cells Sp2/0-Ag14 in vitro to generate hybridoma cells. After cells fusion, the hybridoma cells producing antibody were screened by enzyme-linked immunoadsorbent assay (ELISA), and were subcloned three times by limited dilution. After the hybridoma cells clones were grown up in flasks, cells were harvested and injected intraperitoneally in pristane-primed BALB/c mice (5x10 6 cells/mouse). The ascites were collectd after two weeks and purified by ammonium sulphate precipitation method. The precipitation was then washed once with 45% ammonium sulphate and dissolved in least volumes of phosphate-buffered saline (PBS), dialyzed against PBS for 72 h with several changes. The concentrations of purified ascites were determined by Bradford method. The class and subclass of mAbs were determined by immunoType ™ mouse monoclonal antibody isotyping kit (Thermo Fisher, Waltham, MA, USA, Cat#26178) [18] [19] [20] . Following this process and primary screen, we obtained monoclonal antibodies against ZEBOV GP or VP40, which summarized in Table 1 .
Cell line and plasmids
Human embryonic kidney 293T cells (ATCC, Manassas, VA, USA, Cat#CRL-3216) were cultured in Dulbecco's modified Eagle's medium (DMEM; Thermo Fisher, Waltham, MA, USA, Cat#10566016) containing 10% fetal calf serum (FBS; Gibco, Waltham, MA, USA, Cat#10099141), 2 mM L-glutamine (Life Technologies, Cat#25030081), and 1% penicillin-streptomycin (Life Technologies, Cat#10378016) at 37°C with 5% CO 2 . Plasmids p4cis-vRNA-RLuc, pCAGGS-VP30, pCAGGS-VP35, pCAGGS-NP, pCAGGS-L, pCAGGSTim1, and pCAGGS-T7 were kindly provided by Drs. Heinz Feldmann and Thomas Hoenen, Rocky Mountain Laboratories, National Institute of Health (NIH). The p4cis-vRNA-RLuc contains Zaire EBOV genes (GP1, GP2, VP40, and VP24), non-coding regions, and a reporter gene, is suitable to produce trVLPs and check reporter activity to to detect the level of virus replication.
Production of trVLPs
293T cells (p0) were transfected with plasmids encoding each Zaire EBOV structural protein and a Renilla luciferase reporter (250 ng p4cis-vRNA-RLuc, 75 ng pCAGGS-VP30, 125 ng pCAGGS-VP35, 125 ng pCAGGS-NP, 1, 000 ng pCAGGS-L, pCAGGS-T7) by transfection reagent FuGENE HD (Promega, Madison, WI, USA, Cat#E2311) [21, 22] . Cell supernatant containing released trVLPs was harvested 72 h post transfection, cells and cellular debris were pelleted by gentle centrifugation at 175 × g. The supernatant was then used to infect target 293T cells (p1) previously transfected with RNP components (75 ng pCAGGS-VP30, 125 ng pCAGGS-VP35, 125 ng pCAGGS-NP, 1, 000 ng pCAGGS-L, 250 ng pCAGGS-Tim1). Target 293T cells (p2-p5) were treated in a similar manner. To get the concentrated trVLPs, the total value about 200ml cleared supernatant (33ml cleared supernatants in each pipe) was centrifuged at 25, 000 rpm for 3 h at 4°C with a SW-28 rotor. The resulting pellet was resuspended in 100 μl ice-cold NTE buffer (10 mM Tris, pH 7.5, 100 mM NaCl, 1 mM EDTA). trVLPs were left on ice until use. size; Millipore, Darmstadt, Germany, Cat#SLGP033RB). 293T cells cultured in 8-well Chamber Slides with removable wells were incubated with the DiI-labeled trVLPs at 4°C for 10 min, washed with PBS, and then warmed to 37°C. Then, 4',6-diamidino-2-phenylindole (DAPI, diluted by PBS in 10 μg/ml, Invitrogen, Waltham, MA, USA, Cat#P36931) was added to stain the nucleus. From 10 to 60 min at 37°C, the well was set on the stage of a fluorescence microscope, and the internalization process of DiI-labeled trVLPs in 293T cells was imaged at different time points.
Imaging of the DiI-labeled trVLPs internalization in live 293T cells
Electron microscopy analysis of trVLPs Purified trVLPs (10 μl) were pipetted on 300 mesh copper grid coated with carbon film and incubated for 5 minutes at room temperature. Grids were then washed with clear water and negatively stained for 15 seconds using 1% phosphotungstic acid buffered to pH 7.0 with 1 M ammonium hydroxide. The trVLPs were visualized using a Hitachi H7000 transmission electron microscope.
Neutralization protocol of mAbs against trVLPs trVLPs (MOI=1.5) were added to 3, 5, 10, or 15 μg/ml GP-mAb or the three VP40-mAbs, mixed thoroughly in opti-MEM (Invitrogen, Waltham, MA, USA, Cat#31985070), and incubated at room temperature for 1 h. Then, the compound was added to the 293T cells in 24-well plates (1×10 5 cells/well). Meanwhile, isotype antibody (IgG2a, Abcam, Cambridge, UK, Cat#ab1281) with different concentrations were treated as negative control group. trVLPs (MOI=1.75) were added to the same concentrations of mAbs, and, following the same procedure, the compound was added to the cells in 6-well plates (4×10 5 cells /well). Cells were harvested at 24, 48, and 72 h post treatment and trVLPs -RNA was quantified by qRT-PCR (cells in 24-well plates). TrVLPs -GP was detected by western blot analysis (cells in 6-well plates). trVLPs added to equivalent opti-MEM were set as positive control, normal 293T cells without trVPLs were treated as negative control.
RNA extraction and quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR)
Total RNA was extracted from 293T cells in 24-well plates using TRIzol (Invitrogen, Waltham, MA, USA, Cat#15596018) according to the manufacturer's instruction. qRT-PCR was performed with the ZEBOV nucleic acid test kit (Zhijiang bio-tech, Shanghai, China, Cat#QR-0220-02), on the ABI 7500 qPCR system (45˚C for 10 min, 95˚C for 15 min, one cycle; then, 95˚C for 15 sec, 60˚C for 30 sec, 45 cycles). The positive control, provided by the kit, was serially diluted over three orders of magnitude, and the absolute quantity of trVLPs RNA (copy/ml) was calculated with the Ct and standard curve. All qRT-PCR reactions were performed in triplicate and repeated three independent times.
Immunofluorescence assay 293T cells were cultured on 8-well LabTek II chamber slides (Thermo Scientific, Waltham, MA, USA, Cat#177402PK) and infected with trVLPs (MOI = 1.5) for 72 h. Then, cells were fixed in 4% formaldehyde, washed 3 times with PBS, and permeabilized with 0.5%Triton X-100. Following another three times of PBS washes, cells were blocked in 3% human serum albumin solution for 30 min. The cells were then incubated with anti-EBOV monoclonal antibody (100 μg/ml, Abcam, Cambridge, UK, Cat#ab1924) overnight at 4℃. Following three times of PBS washes, cells were incubated for 1 h at room temperature with Alexa Fluor 488-conjugated anti-human antibody (1:400, Invitrogen, Waltham, MA, USA, Cat#A-10631). Cells were microscopically observed with an Image-Pro Plus image system using a GFP imaging cube. The isotype antibody (IgG2a, Abcam, Cambridge, UK, Cat#ab1281) was used as negative control.
Protein extraction and western blot analysis
Total protein from p1-p5 293T cells was extracted with extraction buffer RIPA (Beyotime, Shanghai, China, Cat#P0013K) with protease inhibitor PMSF (Solarbio, Beijing, China, Cat#P6730). Protein levels were then quantified using the bicinchoninic acid (BCA) method (Sigma, Santa Clara, CA, USA, Cat#BCA1-1KT). Each lane was loaded with 40 μg of protein, run on a 10% SDS-polyacrylamide gel, and transferred onto PVDF membranes (Millipore, Darmstadt, Germany, Cat#K5HA3224L). The membranes were then incubated with mouse monoclonal antibody to ZEBOV GP (10 μg/ml, Abcam, Cat#ab1918), or mouse monoclonal anti GAPDH 
Antibody variable domain sequencing analysis
Total RNA was isolated from frozen hybridoma cell lysates (producing ZJB08-1, A2G7, G7A6, F1B4, respectively) in TRIzol (Invitrogen, Cat#15596-026), then was reverse transcribed into cDNA using universal primers following the protocol of PrimeScript TM 1st Strand cDNA Synthesis Kit (Takara, Dalian, China, Ca# 6110A). The antibody fragments of variable heavy chain and variable light chain were amplified according to the standard operating procedure of rapid amplification of cDNA ends. Then, amplified antibody fragments were cloned into standard cloning vectors separately. Colony PCR was performed to screen the clones with inserts of correct sizes. No less than five colonies with inserts of correct sizes were sequenced for each fragment.
Statistical analysis
The data in normal distribution are presented as the mean ± standard deviation (SD). Two-tailed, paired t-test or unpaired t-test with Welch's correction was performed when appropriate. All analysis was performed by Graphpad Prism 5 (GraphPad Software, UK), and differences between group means with P < 0.05 were considered statistically significant.
Results

Monoclonal antibodies
We produced mAbs against Zaire EBOV GP and VP40, respectively. The anti-GP antibody, ZJEB8-01, targets GP RBD; the anti-VP40 antibody, A2G7, targets VP40 NTD; the anti-VP40 antibodies, G7A6, and F1B4, target VP40 CTD. The detailed information was summarized in Table 1 .
Zaire EBOV-trVLP mimic authentic ebola virion both in morphology and basic function under biosafety level 2 conditions
Zaire EBOV-trVLPs were synthesized from passage 1 to 5. Reporter activity was detected according to the protocol, and increased with each passage (Fig. 1A) . The morphology of trVLPs was visualized with electron microscopy, appeared as filamentous-like structures (Fig.  1B) . This demonstrated that trVLP could mimic the real ebola virion in a considerable degree. Internalization and tracking of DiI-labeled trVLPs in live 293T cells were also visualized by fluorescent microscopy (Fig. 1C) . The images indicated that trVLPs translocated relatively in the cytoplasm over time.
Monoclonal antibodies against GP or VP40 neutralize trVLPs
To test the neutralization effect of the mAbs, trVLPs were incubated with 3, 5, 10, or 15 μg/ml ZJEB8-01, A2G7, G7A6, or F1B4. trVLPs RNA was harvested at 48 h and checked by qRT-PCR ( Fig. 2A-D) . The data indicates that the effective dose of ZJEB8-01 was 5μg/ml (P < 0.05), and that a dose ≥10 μg/ml achieved a significant effect (P < 0.01) (Fig. 2A) . A2G7 was effective at 10 μg/ml or above (P < 0.01) (Fig. 2B ), G7A6 at 5 μg/ml (P < 0.05), with a very significant effect at 15 μg/ml (P < 0.01) (Fig. 2C) . F1B4 was effective at 5 μg/ml (P < Yu et al.: Synergistic Anti-EBV Effect of Mabs 0.05) and highly significant at 10 μg/ml (P < 0.01) (Fig. 2D) . Meanwhile，isotype antibody in different dose was treated as negative control (Fig. 2E) . To confirm the neutralization effect, we verified the dose-response of each of the four mAbs at 5, 10, and 15 μg/ml by western blot. The expression of GP in cell lysate was used to evaluate the level of trVLP and neutralization efforts of the four mAbs. Normal 293T cells without trVLPs infection were set as contrast. Western blot results revealed that the expression of GP decrease with increasing concentrations of mAbs ( Fig. 2F-I ). This data revealed that these mAbs are effective in neutralizing the Zaire EBOV trVLPs. To further support this viewpoint, immunofluorescence was conducted on 293T cells infected by trVLPs which incubated with 5, 10, or 15 μg/ml ZJEB8-01, A2G7, G7A6, or F1B4. 293T cells infected with trVLPs, normal 293T cells without trVLPs were set as controls. Meanwhile, isotype antibody was treated as negative control.
Results showed that with increasing mAbs dosage, the distribution density of GP decreased in the cells (Fig. 2J) . These images data confirmed the neutralization efforts of the mAbs.
Monoclonal antibody cocktail of anti-GP and VP40, and cocktail of multiple anti-VP40-mAbs results in increased neutralization compared to single mAb treatment
Following the confirmation of the neutralization effect of the antibodies, we tested the neutralization of 5, 10, and 15 μg/ml mAbs at 24, 48, and 72 h. To check the synergistic effect, mAbs cocktail of anti-GP and each of the anti-VP40, and a cocktail using the different antiVP40-mAbs (the dose of each mAb in each cocktail was 5 μg/ml) were compared to the results of treatment with one mAb at 10 μg/ml alone (Fig. 3A-E) . Results indicated that the neutralization effect of mAbs at 5 μg/ml had not significantly changed from 24 h to 72 (Fig. 3A) . Each mAbs, at 10 μg/ml, had a significant neutralizing effect at 48 h, with no significant difference at 72 h. However, the mAbs cocktails of ZJEB8-01 (5 μg/ml) and each VP40-mAb (5μg/ml) (ZJEB8-01+A2G7, ZJEB8-01+G7A6, ZJEB8-01+F1B4), and cocktails of two VP40-mAbs (each at 5 μg/ml) (A2G7+G7A6, A2G7+ F1B4, G7A6+ F1B4) displayed better neutralization effects than a single mAb at 10 μg/ml (Fig. 3B) . The 15 μg/ml mAbs had strong neutralization effects compared to the trVLPs group, which did not change over the indicated time points (Fig. 3C) . To confirm the neutralization effects of mAbs cocktail, we performed similar protocols and checked GP expression to evaluate the trVLP levels and neutralization efforts of the four mAbs by western blot. The results clearly demonstrated that GP expression in mAbs cocktail groups, ZJEB8-01 and each VP40-mAb, was reduced 2 . N e u t r a l i z a t i o n effect of the mAbs against trVLPs. (A) 3, 5, 10, and 15 μg/ ml ZJEB8-01 against GP was added to neutralize trVLPs. trVLPs-RNA from 3 identical wells of 3 independent experiments was measured by RT-PCR; trVLPs with only opti-MEM were used as positive control. Similar protocols were performed for (B) A2G7, (C) G7A6, (D) F1B4, and (E) isotype antibody, which was set as negative control. (F) 5, 10, and 15 μg/ ml ZJEB8-01 was added to neutralize trVLPs.
trVLPs-GP was measured by western blot to evaluate the trVLPs levels and n e u t r a l i z a t i o n efforts of the mAb. 293T cells infected with only trVLPs were used as a positive control, and untreated 293T cells were used as a negative control. GAPDH was used as internal reference. Similar protocols were performed with (G) A2G7, (H) G7A6, and (I) F1B4. (J) Immunofluorescence assay of the neutralization effect. 5, 10, and 15 μg/ml mAbs were incubated with infected cells. 293T cells treated with trVLPs only were used as positive control; the isotype antibody group and untreated normal 293T cells were used as negative controls. *, P<0.05; **, P<0.01. 
significantly compared to single-mAb groups (Fig. 3D) . Furthermore, the GP expression in cocktail groups of two VP40-mAbs is significantly lower than in single-mAb groups (Fig. 3E) .
Sequencing analysis of GP-mAb and VP40-mAbs
After identifying the antiviral effect of the above antibodies, we checked the detailed DNA sequences (data are not shown) and amino acid sequences of the four mAbs (Fig. 4A,  4C, 4E, 4G ). The data reveals the heavy and light DNA chains and amino acid sequences for each mAb. Based on the idea of homology modeling, we verified the simulated 3-D structure of the mAbs via SWISS-MODEL software (Fig. 4B, 4D, 4F, 4H ). Those pictures showed that variable regions of both heavy chain and light chain are formed by the folding of different numbers of anti-parallel β sheets, and the hydrophobic amino acids could form an antigen binding groove (indicated by black arrows). h, but not 24 h. The mAbs cocktail of ZJEB8-01 (5 μg/ml) and each VP40-mAb (5 μg/ml) (ZJEB8-01+A2G7, ZJEB8-01+G7A6, ZJEB8-01+F1B4), and cocktail of two VP40-mAbs (each at 5 μg/ml) (A2G7+G7A6, A2G7+ F1B4, G7A6+ F1B4) displayed better neutralization effects than a single mAb at 10 μg/ml. (C) 15 μg/ml mAbs had significant neutralization effects compared with the trVLPs group, but didn't increase over time. (D) Western blot analysis of neutralization effects of ZJEB8-01 (5 μg/ml) and VP40-mAb (5 μg/ml) cocktail. GP was checked to evaluate the trVLPs levels and neutralization efforts of the cocktail. Treatment with single mAb at 10 μg/ml was used as control. (E) Western blot analysis of neutralization effects of VP40-mAbs (each at 5 μg/ml) cocktails. GP was checked to access the trVLPs levels and neutralization efforts of the cocktails. Single mAb at 10 μg/ml was used as control. *, P<0.05; **, P<0.01. 
Discussion
Despite the recent outbreak of the largest EVD in West Africa from December 2013 to March 2016, no vaccines or treatment for EBOV has been approved to date. Currently, The EVD epidemic expedited several promising therapeutics for clinical assessment: (1) small molecule inhibitors, such as BCX4430, GS-5734, AVI-6002, and favipiravir, have been evaluated for the effectiveness against EBOV infection in animal models or in nonrandomized clinical trials [23] [24] [25] [26] ; (2) immune-based therapeutics, including IFNs, plasma transfusion, and mAbs from recovered EVD patients, are evaluated in clinical studies [27] [28] [29] [30] [31] . MAbs are currently one of the most promising treatment options against EVD, which have been confirmed by studies of consistently higher rates of survival in lethally challenged non-human primates. However, limited but promising therapeutic evidence is available in humans [5, 32] . Up to now, over 500 mAbs against EBOV have been extracted from recovered patients [15, 17, 33, 34] or developed from animal models [35, 36] ; however, most of those mAbs have not been checked in clinical trials. To date, about 20 kinds of EBOV mAbs have been identified and characterized, several of them were found promising in non-human primate models, such as mAb114, MIL77E, MB-003, ZMab, and ZMapp TM [5, 6] . Combinations of two or more antibodies probably have synergistic protection by complementary mechanisms, including neutralization-dependent and neutralizationindependent mechanisms. For example, in the ZMAb cocktail, c4G7 and c2G4 are neutralizing, whereas c1H3 is non-neutralizing [37] . In MB-003 cocktail, none mAbs are neutralizing [38] . However, both ZMAb and MB-003 mixtures are protective [39] . It's presumed that nonneutralizing antibodies might confer protection in vivo by preventing budding of nascent virions, which has been confirmed at experiment of inhibition of Marburg virus budding by non-neutralizing antibodies [40] .
Currently, the antiviral therapeutics of mAb-cocktail are limited to anti-GP antibodies, such as ZMAb cocktail, MB-003, and ZMapp TM , while antiviral therapeutics targeting VP40 still underway. As mentioned above, VP40 plays a crucial role in membrane binding, dimerization, oligomerization, make it a promising therapeutic target. Therefore, we synthesized anti-Zaire EBOV GP and VP40 monoclonal antibodies, and characterized the neutralizing effect of anti-GP and VP40 mAbs in vitro. The results suggest that anti-GP or anti-VP40 mAbs effectively inhibit ZEBOV-trVLPs replication in vitro. Furthermore, the cocktail of anti-GP and each anti-VP40 mAb, or cocktail of each two anti-VP40 mAbs has a synergistic anti-viral effect. As demonstrated in this report, anti-GP mAb was designed to target the RBD of GP protein and supposed to inhibit virion entry; F1B4 and G7A6 were designed to target the CTD of VP40, which presumed to interrupt the membrane binding and oligomerization process; A2G7 targets the NTD of VP40, which likely to regulate dimerization and receptor signal transduction. As all four mAbs are IgG1 antibodies, they likely bound to the trVLPs extracellularly and interfered with virus attachment to the cell surface, suppressed membrane fusion and macropinocytosis to prevent virion entry. The viruses budding from the cell surface would then be neutralized by mAbs prior to the next infection. ADCC and complement reaction also has been shown to be induced by anti-GP antibodies [37, 39] . Thus, it's presumably the cocktails of anti-GP and anti-VP40 mAbs neutralize ZEBOV-trVLPs through different simultaneous mechanisms.
Meanwhile, comparing the effective dose of mAbs in our study to other authenticated mAbs is an interesting thing. Our results show that each mAb agaist trVLPs (MOI =1.5) in vitro is among 5-10μg/ml (about 80% neutralization effort), cocktail could reduce the amount of mAbs and achieve better results (greater than 90% neutralization effort). ZMAb (mAb-cocktail of 2G4, 4G7, and 1H3), was estimated at 50% neutralization effort of 0.139μg/ ml in 2G4，0.135μg/ml in 4G7, and 27.6μg/ml in 1H3 [37] . MAb114, achieved half-maximal effective concentration (EC50) at 0.02 μg/ml, and mediated ADCC with maximal activity observed at concentration of 0.03 μg/ml [7] . ZMapp TM (mAb-cocktail of 2G4, 4G7, and 13C6), got EC50 at concentration < 0.1 μg/ml in 2G4, 0.1 μg/ml in 4G7, and 1 μg/ml in 13C6 [5, 41] . These data indicated low doses in antibodies cocktail at EC50. Although the dose of mAbs we developed got relatively high concentration in neutralization effort, it's still worthy of further research in the exact binding epitopes of those antibodies, and anti-virus study in vivo.
This work provides an analysis of anti-virus effects of anti-Zaire EBOV GP and VP40 mAbs. Our data suggest that the anti-GP or anti-VP40 mAbs neutralize Zaire EBOV trVLPs in vitro. Furthermore, a cocktail of anti-GP and anti-VP40 mAb, or of two anti-VP40 mAbs has a synergistic anti-virus effect. This is the first account to report important anti-viral effects of anti-GP and anti-VP40 mAbs cocktail in vitro. This information proves valuable for investigators developing further research in primate models.
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